Quthero is committed to disrupting the ways we treat wounds today – from passive ‘dressing’ of wounds to active, rapid, healthy healing.
We are developing novel, effective and safe treatments for all types of wounds including surgical wounds, burns, and chronic ulcers to accelerate healing, minimize scarring and reduce complications and risks associated with slow healing (infection, pain, amputation and mortality).
Quthero’s patented platform technology enables full epithelial restoration, closing wounds quickly and with minimal scarring. Our biomaterials activate regenerative mechanisms in a potent, paradigm-shifting way with only a single application. This has been demonstrated in multiple pre-clinical animal models and human skin, where Quthero treated wounds healed with minimal scarring and 60-200% faster than the wounds treated with marketed products.
Quthero’s platform technology effectively repairs tissues other than skin as validated in cardiovascular, endothelial, cutaneous tissue, osteoblasts and hiPSC and published in 9 peer reviewed articles.
COO, East River BioSolutions, Inc.
Director Financial Planning and Analysis, Brightstar, Inc.
Director Finance, Kraft Foods, Inc.
Chair of the Board
Professor, University of Toronto
Canada Research Chair
Fellow of the Royal Society of Canada
Co-Founder, TARA Biosystems
Board Member and Business Advisor
Harvard Medical School
Director Contrast Media Chemistry,
Mass. General Hospital
CEO, AZ Therapies
Co-Founder, PureTech Health
Graduate Student in
IBBME, University of Toronto
Professor, Harvard Medical School
Co-founder: Skintifique, Gecko Biomedical, Alivio Therapeutics,
Professor of Surgery, Harvard Medical School
Medical Director, Brigham and Women's Hospital Wound Care Center
Principal Investigator, Wound Healing & Tissue Engineering Laboratory
Clinical Instructor in Surgery, Harvard Medical School
Staff Surgeon, Beth Israel Deaconess Hospital
Founder, Boston Center for Facial Rejuvenation
Sign up to hear from us.